JnJ discontinues mid stage study of skin disease drug
Spring House: Johnson & Johnson has discontinued a mid-stage trial of its experimental drug for moderate to severe atopic dermatitis after the treatment failed to deliver efficacy goals in an interim analysis.
The Phase 2b DUPLEX-AD proof-of-concept study (95475939ADM2001) evaluated JNJ-95475939 (JNJ-5939) for the treatment of moderate to severe atopic dermatitis.
The results of a planned interim analysis met pre specified criteria for early termination of the study, as they did not meet the high-bar efficacy required for advancing clinical development programs for atopic dermatitis.
"Johnson & Johnson is deeply committed to progressing our rich pipeline of clinical-stage and pre-clinical drug candidates for atopic dermatitis," the company stated in a release.
As a chronic and often debilitating disease, where unmet need remains high, atopic dermatitis places both physical and emotional burdens on patients and their families.
The company is developing other experimental treatments for atopic dermatitis, including bispecific antibodies NM26, PX128 and PX130, as well as an oral STAT6 inhibitor, KP‑723, Reuters reported.
Eczema has multiple approved treatments, such as Sanofi and Regeneron's. Dupixent, AbbVie's Rinvoq, Pfizer's Cibinqo, Eli Lilly's Ebglyss, as well as some generic drugs such as cetirizine.
Next Story